Abstract:Poly(ADP-ribose) polymerase (PARP) belongs to family of nuclear proteins having a critical role in base excision DNA repair system by catalysing the process of poly(ADP-ribosyl)ation leading to cell proliferation. The role of PARP inhibitors as anticancer agents was accepted after the approval of olaparib for the treatment of BRCA mutation-induced ovarian cancer. A combined ligand-based and receptor-based approach has been reported here for identification of PARP-1 inhibitors. Seventy one analogues of phthalazinone and 4-carboxamide benzimidazole showing activities against PARP-1 were used to develop ligand-based pharmacophore hypothesis using PHASE. The five-point pharmacophore hypothesis ADHRR.1031 was developed, and atom-based 3D-QSAR studies were carried. The developed 3D QSAR model has good correlation coefficient value (R<sup>2</sup> = 0.952) and cross validated with correlation coefficient value (Q<sup>2</sup> = 0.764). To further ascertain the structural requirement for PARP-1 inhibition, molecular interaction studies of inhibitors with PARP-1 were carried out by performing docking studies using Glide 5.6. Hydrogen bond interaction with Gly202 and Ser243 is an important interaction observed by the carboxyl amide group. The pharmacophore model depicts the importance of the hydrogen bond donor and acceptor nature of the carboxyl amide group. Further multistage virtual screening was performed to screen molecules with possible PARP-1 inhibition. Initial screening was performed based on pharmacophoric features followed by docking that consisted of HTVS, SP, and XP docking and final optimisation by Prime MM-GBSA calculation. The screened molecules were further scrutinised for their ADME-toxicity properties.

Discovery of Potent Isoindolinone Inhibitors That Target an Active Conformation of PARP1 Using DNA‐Encoded Libraries

Potential Biomarkers Of Poly (Adp-Ribose) Polymerase Inhibitors For Cancer Therapy

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

A DNA-encoded library for the identification of natural product binders that modulate poly (ADP-ribose) polymerase 1, a validated anti-cancer target

Discovery of novel anti-tumor compounds targeting PARP-1 with induction of autophagy through in silico and in vitro screening

Discovery of Novel Bromophenol Thiosemicarbazone Hybrids As Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer

PARP1 Inhibitors: Antitumor Drug Design

Discovery of novel PARP-1 inhibitors using tandem in silico studies: integrated docking, e-pharmacophore, deep learning based de novo and molecular dynamics simulation approach

HTS discovery of PARP1-HPF1 complex inhibitors in cancer

Targeted DNA Damage Repair CRISPR/Cas9 Knockout Screen Identifies Novel Classification of Poly-ADP Ribose Polymerase Inhibitors Based on Key Base Excision Repair Proteins

Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors

Design and Synthesis of Benzo-Spirocyclic Derivatives as Potent PARP-1 Inhibitors

Strategic Identification of Anti-Cancer Compounds Targeting PARP15 in DNA Repair Pathways for Enhanced Therapeutic Efficacy

Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor

Understanding structural characteristics of PARP-1 inhibitors through combined 3D-QSAR and molecular docking studies and discovery of new inhibitors by multistage virtual screening

Design and Activity of Novel Oxadiazole Based Compounds That Target Poly(ADP-ribose) Polymerase

The discovery of a potent PARP1 inhibitor Senaparib

Identification of [1,2,4]Triazolo[4,3- a ]pyrazine PARP1 inhibitors with overcome acquired resistance activities

Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy

High-throughput screening assay for PARP-HPF1 interaction inhibitors to affect DNA damage repair